welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Avidity Biosciences Receives Investment from CureDuchenne
Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, announced today that CureDuchenne has made an equity investment in the company. Funding will help to advance pre-clinical development of potential therapies to treat patients with Duchenne muscular dystrophy (DMD).
rareRelated
-
Volker Straub, MD, PhDProfessor Volker Straub was founding joi...
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duc...The purpose of this study is to evaluate...
-
Concept of Gene Therapy for DMD: Jerry R. Mendell, MDhttps://www.youtube.com/watch?v=llqGu7oj...
-
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)HOPE-2 is a double-blind clinical trial ...
-
A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)This Phase IIb study is a randomized, do...
-
Archived drug prevents Duchenne muscular dystrophy muscle loss in miceA drug that showed promise in clinical t...
-
Study of ACE-031 in Subjects With Duchenne Muscular DystrophyThe purpose of this study is to determin...
-
NIH Awards $86 Million to Improve Genome Editing TechniquesSomatic Cell Genome Editing support is a...
-
Upgrading the toolbox for Duchenne muscular dystrophy research with a new rabbit modelResearch to improve our understanding of...
